{"id":827980,"date":"2025-03-20T08:14:50","date_gmt":"2025-03-20T12:14:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/"},"modified":"2025-03-20T08:14:50","modified_gmt":"2025-03-20T12:14:50","slug":"second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/","title":{"rendered":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor in metastatic breast cancer <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA)<\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, March  20, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_GKuxFKIzIsQeBz4oMxJXwAvpRMuRQhp2KvSgJY0fh6_EnZOx1UY0vIJLXgrvCstGkSVZEnduhfeKF7EPxjX06tNxl0_o_CJzTMmDcAv08KTakJfZlJcRmgKBSlXUJmH\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>) and recommended continuation of the ongoing study without any modifications. BriaCell\u2019s pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration (FDA).<\/p>\n<p align=\"justify\">\u201cWe are very pleased with the safety and tolerability profile of Bria-IMT plus immune checkpoint inhibitor (CPI) combination in metastatic breast cancer to date,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cThe DSMB&#8217;s second positive data review and recommendation to continue with patient enrollment in BriaCell\u2019s pivotal Phase 3 study clinical trial is highly encouraging and further highlights the potential of our groundbreaking novel immunotherapy to treat this urgent medical need.\u201d<\/p>\n<p align=\"justify\">\u201cMetastatic breast cancer is a devastating disease for patients and their families, and the DSMB\u2019s positive review represents an important step forward towards our goal of transforming cancer care, and improving patients\u2019 survival and quality of life outcomes,\u201d noted Giuseppe Del Priore, MD, MPH, BriaCell\u2019s Chief Medical Officer. \u201cWe look forward to sharing additional updates from BriaCell\u2019s pivotal Phase 3 trial in the coming months.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CzgNKjsHp7LsFVQm2YDtDaXO02bD8yAubwg-R1SGWhvLzu6bhnH7OaAdaEVEYJij7D9DXh14T4yTWKDbSZYDC7DiI5twoz9_a0CdDIZUIuU=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell\u2019s clinical advancement of Bria-IMT as a safe and effective treatment option for metastatic cancer patients; the ability of Bria-IMT to transform cancer care in metastatic breast cancer patients; the potential use of the combination regimen for metastatic breast cancer patients; the potential of BriaCell\u2019s novel immunotherapy to be a groundbreaking treatment for metastatic breast cancer; and BriaCell sharing additional updates about its pivotal Phase 3 trial in the coming months, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z64QPWDm-TsPYaHR9miaTTrpLQX0Zz7mT2waFN--6pNyWLONjbuVfSvaJCBt0cxypkqmtc5Dvc97HoQ6DCnqIC6qyzp79zW5isjvChiHXsM=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z64QPWDm-TsPYaHR9miaTY-EayF1LFVdqGCN6iGERlSru_YWTp7Pw4sklVJjEnh0JSTheaSvE8Egq-nBiGHNHQ==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KurR_ciXQMxffZKiDfETa2vCrVoOLSo2zIT0gNVJdjkxkORYTmcxouM-dtnwJuFU3ylIQhmu2M6kpjrlG3dXI2zh6lf36LeJXlDQsdzefxM=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xY21WGlLwV4e3Vxyug8Cs6B3TbjkCjMS6iGKLhISys6C4wxcuvMpM9JMiLeOlZgRXXgljloGFTanKKDeh1OYYJXrq8_xj_9B06nb0BdX9_g=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzUyYWY3ZGQtZGU0MS00ZGM4LTkyZmEtNzRjYjRiOTE5ZjQ2LTExMDIyMjktMjAyNS0wMy0yMC1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA) PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827980","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA) PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be &hellip; Continue reading &quot;Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T12:14:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer\",\"datePublished\":\"2025-03-20T12:14:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/\"},\"wordCount\":736,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/\",\"name\":\"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=\",\"datePublished\":\"2025-03-20T12:14:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk","og_description":"The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA) PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be &hellip; Continue reading \"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T12:14:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer","datePublished":"2025-03-20T12:14:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/"},"wordCount":736,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/","name":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=","datePublished":"2025-03-20T12:14:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzkyMCM2ODE1OTAwIzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacells-phase-3-study-in-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell\u2019s Phase 3 Study in Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827980"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827980\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}